Latest Period
n/a
Security Snapshot
Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) Institutional Ownership
CUSIP: 23254L801
13F Institutional Holders and Ownership History from Q4 2023 to Q3 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.32
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.001 par value
- Symbol
- CYCC on Nasdaq
- Shares outstanding
- 1,584,707
- Price per share
- $0.32
- Price from insider filings
- $0.32
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CYCC - Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 23254L801.
- Latest finished 13F holder period is not available.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 0 to 0 between Q2 2025 and Q3 2025.
- Reported value moved from $0 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Investment Quick Answers
What is CUSIP 23254L801?
CUSIP 23254L801 identifies CYCC - Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23254L801:
Significant Owners of Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Doris Wong Sing Ee | 70% | $58,388,646 | 194,628,820 | Doris Wong Sing Ee | 26 Feb 2025 | |||
| ARMISTICE CAPITAL, LLC | 9.2% | -7.9% | $7,453,418 | +$7,200,909 | 24,844,725 | +2852% | Armistice Capital, LLC | 31 Mar 2025 |
Institutional Holders of Cyclacel Pharmaceuticals, Inc. - Common Stock, $0.001 par value (CYCC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 0 | $0 | -$56 | $0.32 | 0 |
| 2025 Q2 | 0 | $0 | -$454,117 | $0.32 | 0 |
| 2025 Q1 | 1,626,479 | $454,098 | +$256,529 | $0.28 | 20 |
| 2024 Q4 | 704,042 | $264,346 | +$188,225 | $0.38 | 17 |
| 2024 Q3 | 202,365 | $200,198 | -$40,809 | $0.99 | 14 |
| 2024 Q2 | 229,309 | $371,012 | +$262,753 | $1.62 | 16 |
| 2024 Q1 | 60,593 | $126,739 | -$90,802 | $2.11 | 12 |
| 2023 Q4 | 93,921 | $249,543 | +$249,543 | $2.67 | 13 |